Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04857528 · ClinicalTrials.gov registry record
Detecting HPV DNA in Anal and Cervical Cancers
A clinical trial of Cervical Cancer and Anal Cancer, sponsored by University of Chicago.
- Recruiting
- Registry status
- 20
- Enrollment target
- 2
- Study locations
NCT04857528 is a study of Cervical Cancer and Anal Cancer that is actively recruiting participants, run by University of Chicago. The registered enrollment target is 20 participants, below the 570-participant average among 144 other Cervical Cancer trials with a reported enrollment target (96% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT04857528, a study of Cervical Cancer and Anal Cancer, is actively recruiting participants, sponsored by University of Chicago.
- RECRUITING
- Registry status
- 20 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a research study for individuals who have cancer associated with human papillomavirus (HPV) and are being treated with radiation as part of standard care for their cancer. Doctors leading this study will use blood tests to find out if they can detect the HPV virus in the blood of study participants before, during, and after radiation treatment. They will also collect blood and archival tumor tissue (from a previous biopsy) to perform other tests in the future that could provide more information about HPV-associated cancers and how they respond to treatment. Participation in this study will last approximately 2 years.
Conditions Studied
Interventions
- OTHER Blood Sample Collection
- RADIATION Radiation Treatment With or Without Chemotherapy
- DIAGNOSTIC_TEST HPV Genotyping (HPV DNA Test)
- DIAGNOSTIC_TEST Testing Archival Tumor Tissue
- OTHER Physical Exam
Study Locations (2)
Illinois
- University of Illinois at Chicago - Chicago
- University of Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2020-10-06 |
| Est. Completion | 2027-11-15 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04857528
The ClinicalTrials.gov registry entry for NCT04857528 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 570-participant average among 144 other Cervical Cancer trials with a reported enrollment target (96% lower). The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Cervical Cancer appearing as the primary indexed condition, and to 5 interventions - of which Blood Sample Collection is the first listed.
NCT04857528 reports 2 study locations spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT04857528 about?
NCT04857528 is a clinical study titled "Detecting HPV DNA in Anal and Cervical Cancers". This is a research study for individuals who have cancer associated with human papillomavirus (HPV) and are being treated with radiation as part of standard care for their cancer. Doctors leading this study will use blood tests to find out if they can detect the HPV virus in the blood of study parti...
What is the current status of trial NCT04857528?
This trial is currently recruiting. The enrollment target is 20 participants. The study started on 2020-10-06. Estimated completion is 2027-11-15.
What conditions does trial NCT04857528 study?
This clinical trial studies the following conditions: Cervical Cancer, Anal Cancer, HPV-Related Carcinoma, HPV-Related Cervical Carcinoma, HPV-Related Anal Squamous Cell Carcinoma.
What interventions are being tested in trial NCT04857528?
The interventions under investigation include: Blood Sample Collection (OTHER), Radiation Treatment With or Without Chemotherapy (RADIATION), HPV Genotyping (HPV DNA Test) (DIAGNOSTIC_TEST), Testing Archival Tumor Tissue (DIAGNOSTIC_TEST), Physical Exam (OTHER).
Who is sponsoring clinical trial NCT04857528?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04857528 being conducted?
This trial has 2 study locations across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cervical Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Biological Drivers of Cervical Cancer and Side Effects From Radiation Therapy
RECRUITING
-
PRGN-2009 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer
RECRUITING · Phase 2
-
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 2
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
-
PopSci CHW4CervixHealth
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.